Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Triptorelin (Decapeptyl SR) for premenopausal women with early endocrine responsive breast cancer. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' objectives Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause. However, younger women, and in rare cases, men, may also get breast cancer.
There are many types of breast cancer. Triptorelin is a new treatment for a type of early breast cancer that usually occurs in younger women who have not gone through the menopause, and is described as hormone receptor-positive. Triptorelin is given as an injection straight into a muscle every 28 days along with hormonal therapy tablets that are already widely used for breast cancer. Studies at the moment are aiming to show how well these treatments work together and that triptorelin is safe to use.
If triptorelin is licenced for use in the UK, it will provide a new treatment option for this patient group. Indexing Status Subject indexing assigned by CRD MeSH Breast; Breast Neoplasms; Endocrine Gland Neoplasms; Female; Humans; Premenopause; Triptorelin Pamoate Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000437 Date abstract record published 04/03/2016 |